Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 8, 2017, Pages 2018-2023

  Qi, Hangfei ^a   Chu, Virginia ^b   Wu, Nicholas C ^b   Chen, Zugen ^a   Truong, Shawna ^b   Brar, Gurpreet ^a   Su, Sheng Yao ^c,d   Du, Yushen ^a,e   Arumugaswami, Vaithilingaraja ^a   Olson, C Anders ^a   Chen, Shu Hua ^d   Lin, Chung Yen ^d   Wu, Ting Ting ^a   Sun, Ren ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d INSTITUTE OF INFORMATION SCIENCE   (Taiwan)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

HCV; High throughput mutagenesis; IF6 16 antiviral function; Innate immune evasion mechanism; p7 ion channel protein

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; CORE PROTEIN; NONSTRUCTURAL PROTEIN 5A; P7 PROTEIN; UNCLASSIFIED DRUG; VIRAL PROTEIN; IFI6 PROTEIN, HUMAN; INTERFERON; MITOCHONDRIAL PROTEIN; P7 PROTEIN, HEPATITIS C VIRUS;

3' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; ECTOPIC EXPRESSION; HEK293 CELL LINE; HEPATITIS C VIRUS; IMMUNE EVASION; INNATE IMMUNITY; INTERFERON PRODUCTION; MITOCHONDRIAL MEMBRANE POTENTIAL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION; CELL LINE; CRISPR CAS SYSTEM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE KNOCKOUT; GENE LIBRARY; GENETICS; HEPACIVIRUS; HEPATITIS C; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; LIVER; METABOLISM; PATHOGENICITY; VIROLOGY;

CELL LINE; CRISPR-CAS SYSTEMS; GENE EXPRESSION PROFILING; GENE KNOCKOUT TECHNIQUES; GENE LIBRARY; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTERFERONS; LIVER; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL PROTEINS; MUTAGENESIS, INSERTIONAL; SIGNAL TRANSDUCTION; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 85013298065     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1614623114     Document Type: Article

References (65)

1. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345(1):41-52.
2. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7(8):448-458.
3. Ferenci P (2015) Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol 12(5):284-292.
4. Kowdley KV, et al.; ION-3 Investigators (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370(20):1879-1888.
5. Afdhal N, et al.; ION-2 Investigators (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370(16):1483-1493.
6. Afdhal N, et al.; ION-1 Investigators (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370(20):1889-1898.
7. Ferenci P, et al.; PEARL-III Study; PEARL-IV Study (2014) ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370(21):1983-1992.
8. Lawitz E, et al. (2014) Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 383(9916):515-523.
9. Liang TJ (2013) Current progress in development of hepatitis C virus vaccines. Nat Med 19(7):869-878.
10. Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436(7053):933-938.
11. Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM (2007) Studying hepatitis C virus: Making the best of a bad virus. J Virol 81(17):8853-8867.
12. Lemon SM (2010) Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 285(30):22741-22747.
13. Gale M, Jr, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436(7053):939-945.
14. Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436(7053):967-972.
15. Katze MG, He Y, Gale M, Jr (2002) Viruses and interferon: A fight for supremacy. Nat Rev Immunol 2(9):675-687.
16. Meylan E, et al. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062):1167-1172.
17. Loo Y-M, et al. (2006) Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 103(15):6001-6006.
18. Li K, et al. (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 102(8):2992-2997.
19. Lin W, et al. (2006) Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 80(18):9226-9235.
20. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM (1999) Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285(5424):107-110.
21. Gale MJ, Jr, et al. (1997) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230(2):217-227.
22. Gale M, Jr, et al. (1998) Control of PKR protein kinase by hepatitis C virus non-structural 5A protein: Molecular mechanisms of kinase regulation. Mol Cell Biol 18(9):5208-5218.
23. Garaigorta U, Chisari FV (2009) Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 6(6):513-522.
24. Itsui Y, et al. (2006) Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat 13(10):690-700.
25. Itsui Y, et al. (2009) Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology 50(6):1727-1737.
26. Zhu H, et al. (2003) Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 37(5):1180-1188.
27. Wilkins C, et al. (2012) IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57(2):461-469.
28. Randall G, et al. (2006) Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131(5):1584-1591.
29. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR (2005) Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 42(3):702-710.
30. Jiang D, et al. (2008) Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 82(4):1665-1678.
31. Schoggins JW, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344):481-485.
32. Su AI, et al. (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99(24):15669-15674.
33. Bigger CB, et al. (2004) Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78(24):13779-13792.
34. Bièche I, et al. (2005) Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 332(1):130-144.
35. Geiss GK, et al. (2003) Gene expression profiling of the cellular transcriptional network regulated by alpha/beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J Virol 77(11):6367-6375.
36. Qi H, et al. (2014) A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. PLoS Pathog 10(4):e1004064.
37. Remenyi R, et al. (2014) A comprehensive functional map of the hepatitis C virus genome provides a resource for probing viral proteins. MBio 5(5):e01469-e14.
38. Enomoto N, et al. (1995) Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96(1):224-230.
39. Enomoto N, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334(2):77-81.
40. Duverlie G, et al. (1998) Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79(Pt 6):1373-1381.
41. Nousbaum J, et al. (2000) Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74(19):9028-9038.
42. El-Shamy A, et al. (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48(1):38-47.
43. Sumpter R, Jr, et al. (2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79(5):2689-2699.
44. Marukian S, et al. (2011) Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology 54(6):1913-1923.
45. Bigger CB, Brasky KM, Lanford RE (2001) DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 75(15):7059-7066.
46. Tahara E, Jr, et al. (2005) G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother 54(8):729-740.
47. Cheriyath V, et al. (2012) G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene 31(17):2222-2236.
48. Qi Y, et al. (2015) IFI6 inhibits apoptosis via mitochondrial-dependent pathway in Dengue virus 2 infected vascular endothelial cells. PLoS One 10(8):e0132743.
49. Maro B, Marty MC, Bornens M (1982) In vivo and in vitro effects of the mitochondrial uncoupler FCCP on microtubules. EMBO J 1(11):1347-1352.
50. Sadler AJ, Williams BRG (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8(7):559-568.
51. Katze MG, Fornek JL, Palermo RE, Walters KA, Korth MJ (2008) Innate immune modulation by RNA viruses: Emerging insights from functional genomics. Nat Rev Immunol 8(8):644-654.
52. Bowie AG, Unterholzner L (2008) Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8(12):911-922.
53. Lau DTY, et al. (2008) Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 47(3):799-809.
54. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR (1984) Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38(3):745-755.
55. Kelly JM, Gilbert CS, Stark GR, Kerr IM (1985) Differential regulation of interferon-induced mRNAs and c-myc mRNA by α- and γ-interferons. Eur J Biochem 153(2):367-371.
56. Revel M, Chebath J (1986) Interferon-activated genes. Trends Biochem Sci 11(4):166-170.
57. Kusari J, Tiwari RK, Kumar R, Sen GC (1987) Expression of interferon-inducible genes in RD-114 cells. J Virol 61(5):1524-1531.
58. Martensen PM, Justesen J (2004) Small ISGs coming forward. J Interferon Cytokine Res 24(1):1-19.
59. Fink J, et al. (2007) Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis 1(2):e86.
60. Cheriyath V, Leaman DW, Borden EC (2011) Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer. J Interferon Cytokine Res 31(1):173-181.
61. Porter ACG, Itzhaki JE (1993) Gene targeting in human somatic cells. Complete inactivation of an interferon-inducible gene. Eur J Biochem 218(2):273-281.
62. Schoggins JW, et al. (2012) Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci USA 109(36):14610-14615.
63. Li J, et al. (2013) A short hairpin RNA screen of interferon-stimulated genes identifies a novel negative regulator of the cellular antiviral response. MBio 4(3):e00385-e13.
64. Zhao D, Peng D, Li L, Zhang Q, Zhang C (2008) Inhibition of G1P3 expression found in the differential display study on respiratory syncytial virus infection. Virol J 5(1):114.
65. Arumugaswami V, et al. (2008) High-resolution functional profiling of hepatitis C virus genome. PLoS Pathog 4(10):e1000182.